Insulin Efsitora a Useful Addition to Treatment of Type 2 Diabetes but not Type 1 Diabetes
International Journal of Diabetes Management · 31.12.2024 · 3 (2)
DOI: 10.61797/ijdm.v3i2.355 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Diabetes Management, online erschienen am 31.12.2024. Verfasst von Nasser Mikhail. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Efsitora is a once-weekly basal insulin under investigation in a series of 5 phase 3 clinical trials called the QWINT development program. In QWINT-2 and QWINT-5 trials including insulin-naïve patients with type 2 diabetes and adults with type 1 diabetes, respectively, efsitora was compared to once-daily degludec. In both trials, efsitora was found non inferior to degludec in lowering glycated hemoglobin (HbA1c) levels after 52 weeks. In patients with type 2 diabetes, 6 episodes of level 3 hypoglycemia (i.e. severe hypoglycemia associated with cognitive impairment) occurred with degludec versus none with efsitora. However, incidence of level 1 hypoglycemia or hypoglycemia alert [blood glucose (BG) 54-69 mg/dl] was numerically greater with efsitora versus degludec, estimated rate ratio (ERR) 1.24 (95% CI, 0.99-1.55). Moreover, rates of level 2 hypoglycemia or clinically significant hypoglycemia (BG
Zitieren
APA
Mikhail, N. (2024). Insulin Efsitora a Useful Addition to Treatment of Type 2 Diabetes but not Type 1 Diabetes. International Journal of Diabetes Management, 3(2). https://doi.org/10.61797/ijdm.v3i2.355
Vancouver
Mikhail N. Insulin Efsitora a Useful Addition to Treatment of Type 2 Diabetes but not Type 1 Diabetes. International Journal of Diabetes Management. 2024;3(2). doi:10.61797/ijdm.v3i2.355
BibTeX
@article{Mikhail2024,
author = {Mikhail, Nasser},
title = {Insulin Efsitora a Useful Addition to Treatment of Type 2 Diabetes but not Type 1 Diabetes},
journal = {International Journal of Diabetes Management},
year = {2024},
volume = {3},
number = {2},
doi = {10.61797/ijdm.v3i2.355}
}
EUVIMED